Patents by Inventor Paul Gregorevic

Paul Gregorevic has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SMAD7 gene delivery into muscle cells
    Patent number: 11268107
    Abstract: Described herein are vectors, such as adeno-associated virus (AAV) vectors, and recombinant AAV expressing Smad7. The disclosed AAV vectors and rAAV can be used for therapeutic applications in the treatment and amelioration of muscle wasting, cardiac and/or skeletal muscle wasting associated with cancer cachexia.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: March 8, 2022
    Assignees: Washington State University, Baker Heart and Diabetes Institute
    Inventors: Buel Dantese Rodgers, Paul Gregorevic
  • SMAD7 GENE DELIVERY AS A THERAPEUTIC
    Publication number: 20180112232
    Abstract: Described herein are vectors, such as adeno-associated virus (AAV) vectors, and recombinant AAV expressing Smad7. The disclosed AAV vectors and rAAV can be used for therapeutic applications in the treatment and amelioration of muscle wasting, cardiac and/or skeletal muscle wasting associated with cancer cachexia.
    Type: Application
    Filed: April 22, 2016
    Publication date: April 26, 2018
    Applicants: Washington State University, Baker Heart and Diabetes Institute
    Inventors: Buel Dantese Rodgers, Paul Gregorevic
  • Compositions and methods for systemic nucleic acid sequence delivery
    Patent number: 7655467
    Abstract: The present invention provides systemic nucleic acid sequence delivery without conventional systemic administration aids (SAAs). In certain embodiments, vascular permeability agents (VPAs), such as VEGF, are used in conjunction with nucleic acid viral vectors, such as adeno-associated virus (AAV). The present invention also provides methods of treating disease by co-administration of nucleic cid sequences encoding Igf-1 and dystrophin or dystrophin-like proteins.
    Type: Grant
    Filed: November 15, 2004
    Date of Patent: February 2, 2010
    Assignee: The University of Washington
    Inventors: Jeffrey S. Chamberlain, Paul Gregorevic, Michael J. Blankinship, James M. Allen
  • Compositions and methods for systemic nucleic acid sequence delivery
    Publication number: 20050158281
    Abstract: The present invention provides systemic nucleic acid sequence delivery without conventional systemic administration aids (SAAs). In certain embodiments, vascular permeability agents (VPAs), such as VEGF, are used in conjunction with nucleic acid viral vectors, such as adeno-associated virus (AAV). The present invention also provides methods of treating disease by co-administration of nucleic cid sequences encoding Igf-1 and dystrophin or dystrophin-like proteins.
    Type: Application
    Filed: November 15, 2004
    Publication date: July 21, 2005
    Applicant: The University of Washington
    Inventors: Jeffrey Chamberlain, Paul Gregorevic, Michael Blankinship, James Allen